Live feed
Filing
SCHEDULE 13G
SCHEDULE 13G0000102909-26-000077·Amylyx Pharmaceuticals, Inc.
Schedule 13G ownership disclosure
Amylyx Pharmaceuticals Inc
Common Stock · CUSIP: 03237H101
Event date: 2025-12-31
- Filing-level shares
- 5,804,912
- Percent of class
- 5.28%
- The Vanguard Group
Shares: 5,804,912 · Class: 5.28%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000102909-26-000077
- Form type
- SCHEDULE 13G
- Filer
- Amylyx Pharmaceuticals, Inc.
- CIK
- CIK 1658551
- Filed
- Jan 30, 2026
- Reporting period
- Dec 31, 2025
- Description
- Schedule 13G beneficial ownership